On March 5, 2025 Sanofi reported that it has successfully priced its offering of EUR 1.5 billion of notes across 2 tranches (Press release, Sanofi, MAR 5, 2025, View Source [SID1234650978]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

•
€850 million floating rate notes, due March 2027, bearing interest at 3-month Euribor plus 0.300%

•
€650 million fixed rate notes, due March 2031, bearing interest at an annual rate of 2.750%.

The notes are being issued off the company’s Euro Medium Term Note Program.

Sanofi intends to use the net proceeds of the offering for general corporate purposes.

The transaction has been led by Deutsche Bank and J.P. Morgan as Global Coordinators, and ING, Santander CIB and Unicredit, all as Joint Lead Managers.